Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
LAWRENCEVILLE, N.J., May 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9, 2018 at Reed Smith, LLP in New York City. Mr. Tardugno’s presentation details are as follows:
Corporate Presentation:
- Date and Time: Tuesday, May 8, 2017 at 9:30 a.m. – 9:50 a.m. EDT
- Location: Room A/B
Slide Presentation Available on Celsion’s Website
To view Mr. Tardugno’s slide presentation from the event, please visit Celsion’s corporate website at http://investor.celsion.com/financial-events .
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
